Dendreon to Hold a Conference Call Tomorrow at 9:00 AM ET to Discuss Final Results of Phase 3 PROVENGE IM... ( SEATTLE April 13 /- Dendreon Corporat...)

Dendreon to Hold a Conference Call Tomorrow at 9:00 AM ET to Discuss Final Results of Phase 3 PROVENGE IMPACT Trial

Date:4/13/2009

SEATTLE, April 13 /PRNewswire-FirstCall/ -- Dendreon Corporation (Nasdaq: DNDN) will host a conference call tomorrow, Tuesday, April 14, 2009, at 9:00 AM ET (6:00 AM PT) to review the outcome of the FINAL analysis of its IMPACT (IMmunotherapy for Prostate AdenoCarcinoma Treatment, also known as D9902B) clinical trial of PROVENGE(R) (sipuleucel-T), the Company's investigational active cellular immunotherapy for the treatment of advanced prostate cancer.

Those interested may access the call with the following information:

    Time:     9:00 AM ET/6:00 AM PT
    Date:     April 14, 2009
    Dial-in:  1-877-419-6594 (domestic) or +1-719-325-4855 (international)
    Webcast:  www.dendreon.com (homepage and investor relations section)

A recorded rebroadcast will be available for interested parties unable to participate in the live conference call by dialing 888-203-1112 or 719-457-0820 for international callers; the conference ID number is 8182435. The replay will be available from 12:00 pm ET on April 14, 2009 until midnight ET on April 16, 2009. In addition the webcast will be archived for on-demand listening for 30 days at www.dendreon.com.

About Dendreon

Dendreon Corporation is a biotechnology company whose mission is to target cancer and transform lives through the discovery, development and commercialization of novel therapeutics. The Company applies its expertise in antigen identification, engineering and cell processing to produce active cellular immunotherapy product candidates designed to stimulate an immune response. Dendreon is also developing an orally-available small molecule that targets TRPM8 that could be applicable to multiple types of cancer as well as benign prostatic hyperplasia. The Company has its headquar
'/>"/>

SOURCE Dendreon Corporation
Copyright©2009 PR Newswire.
All rights reserved

1

GOOD

Page: 1 2
Related medicine technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. Dendreon Completes Target Enrollment of 500 Patients in Phase 3 IMPACT Study of Provenge(R) For Advanced Prostate Cancer
3. Dendreon Presents Data Correlating the Cumulative Potency of PROVENGE(R) to Overall Survival
4. Dendreon Presents Preclinical Data Demonstrating Activity of Trp-p8 agonist, D-3263, in Benign Prostatic Hyperplasia
5. Dendreon Initiates Phase 2 Trial of PROVENGE in Patients With Localized Prostate Cancer Prior to Surgery
6. Dendreon Expects Interim Data Analysis for Phase 3 PROVENGE IMPACT Trial in October
7. Dendreon to Hold a Conference Call Today at 9:00 AM ET to Provide an Update on Interim Results of Phase 3 PROVENGE IMPACT Trial
8. Dendreon Announces Interim Data From Phase 3 PROVENGE IMPACT Trial
9. Dendreon Presents Integrated Analysis of Clinical Data from NEUVENGE Trials at Chemotherapy Foundation Symposium
10. Genaera Corporation Presents Interim Phase 1 Data for Obesity Compound Trodusquemine (MSI-1436) at IBC Conference
11. Intellect Neurosciences, Inc. to Present Data on Alzheimers Vaccine at 13th International Congress of Immunology Conference

Post Your Comments:

(Date:12/1/2009)... Dec. 1 CCS Medical, Inc. a leadin... today announced that it has received approval fro...of Delaware (the "Court") for its bidding procedur...ale of substantially all of its assets. ,, Purs...t approved bidding procedures for the sale of subs...

(Date:12/1/2009)... 1 CEL-SCI Corporation (...nd a developer of vaccines and therapeutics for th... announced today that it has retained the services...n (CRO) to run CEL-SCI,s upcoming Phase III clinic...with the Company,s lead product candidate, Multiki...

(Date:12/1/2009)... Dec. 1 MedQuist Inc. ...-enabled clinical documentation services, today an...dial Design, Inc. has been integrated with SpeechQ...cognition system. The solution is being demonstrat...SNA) convention November 29 through December 2. ...

Breaking Medicine Technology:CCS Medical Wins Approval from Bankruptcy Court for Its Chapter 11 Asset Sale Bidding Procedures 2 CEL-SCI Retains Global Contract Research Organization to Manage Upcoming Phase III Clinical Trial for Its Cancer Drug Multikine 2 CEL-SCI Retains Global Contract Research Organization to Manage Upcoming Phase III Clinical Trial for Its Cancer Drug Multikine 3 MedQuist Integrates Search Engine from Primordial with SpeechQ(TM) for Radiology 2 Insmed Announces Addition to the Russell 3000 28R 29 Index 12842 1 Insmed Announces Addition to the Russell 3000 28R 29 Index 12842 2 EFSA Issues Positive Safety Statement for the Use of Chromium Picolinate in EU Food Supplements 12841 1 EFSA Issues Positive Safety Statement for the Use of Chromium Picolinate in EU Food Supplements 12841 2 EFSA Issues Positive Safety Statement for the Use of Chromium Picolinate in EU Food Supplements 12841 3 EFSA Issues Positive Safety Statement for the Use of Chromium Picolinate in EU Food Supplements 12841 4 YoCream Announces the First Soft Serve Frozen Yogurt With Beneficial Probiotics Clinically Proven to Strengthen the Digestive System 50368 1 YoCream Announces the First Soft Serve Frozen Yogurt With Beneficial Probiotics Clinically Proven to Strengthen the Digestive System 50368 2 YoCream Announces the First Soft Serve Frozen Yogurt With Beneficial Probiotics Clinically Proven to Strengthen the Digestive System 50368 3 YoCream Announces the First Soft Serve Frozen Yogurt With Beneficial Probiotics Clinically Proven to Strengthen the Digestive System 50368 4

[0] CCS Medical Wins Approval from Bankruptcy Court for Its Chapter 11 Asset Sale Bidding Procedures [0] CEL-SCI Retains Global Contract Research Organization to Manage Upcoming Phase III Clinical Trial for Its Cancer Drug Multikine [0] MedQuist Integrates Search Engine from Primordial with SpeechQ(TM) for Radiology

...-Company to Host Conference Call at 9:00 a.m. EDT-... Corp. (Nasdaq: MEMY ) today announced top-line d...d, placebo-controlled Phase 2a study,of MEM 1003, ...zheimer,s,disease. The trial enrolled 183 subjects... 40 centers in the United States and included mono...

...ORLANDO, Fla., Oct. 13 Acutely ill, hospitalized,...rovement in symptoms,after taking INVEGA(TM) (pali...SEROQUEL(R)(a) (quetiapine) and placebo. Symptom i...ve days into therapy and continued,through the end...inary data,presented today at the 20th Annual U.S....

Other Medicine Technology:Memory Pharmaceuticals Announces Results for Phase 2a Trial of MEM 1003 in Alzheimer's Disease 2 Memory Pharmaceuticals Announces Results for Phase 2a Trial of MEM 1003 in Alzheimer's Disease 3 Memory Pharmaceuticals Announces Results for Phase 2a Trial of MEM 1003 in Alzheimer's Disease 4 INVEGA(TM) Significantly Reduced Symptoms of Schizophrenia Compared to SEROQUEL(R) in Acutely Ill, Hospitalized Patients 2 INVEGA(TM) Significantly Reduced Symptoms of Schizophrenia Compared to SEROQUEL(R) in Acutely Ill, Hospitalized Patients 3 INVEGA(TM) Significantly Reduced Symptoms of Schizophrenia Compared to SEROQUEL(R) in Acutely Ill, Hospitalized Patients 4 INVEGA(TM) Significantly Reduced Symptoms of Schizophrenia Compared to SEROQUEL(R) in Acutely Ill, Hospitalized Patients 5 INVEGA(TM) Significantly Reduced Symptoms of Schizophrenia Compared to SEROQUEL(R) in Acutely Ill, Hospitalized Patients 6 INVEGA(TM) Significantly Reduced Symptoms of Schizophrenia Compared to SEROQUEL(R) in Acutely Ill, Hospitalized Patients 7

Memory Pharmaceuticals Announces Results for Phase 2a Trial of MEM 1003 in Alzheimer's Disease INVEGA(TM) Significantly Reduced Symptoms of Schizophrenia Compared to SEROQUEL(R) in Acutely Ill, Hospitalized Patients

(Date:12/1/2009)...Could identify those who would benefit from liver ...UESDAY, Dec. 1 (HealthDay News) -- A CT scan of li...er may help predict overall survival after chemoth... (Avastin) to cytotoxic chemotherapy has been show...colorectal cancer and to produce better results in...

(Date:12/1/2009)... , MIAMI, FL (December 1, 2009)The Clinical Resea...ler School of Medicine, has been honored for its s... the LEED designation, established by the U.S. Gre...ding Certification Institute (GBCI). LEED is the n...ction and operation of green buildings., "Having ...

(Date:12/1/2009)..., , SMITHFIELD, R.I., Dec...ective equipment, bad assumptions are hazardous an...5 years of government regulation, a handful of per...ing both the effectiveness of occupational Hearin...ing. ,, A new free, white paper from Howard Le...

(Date:12/1/2009)..., , WASHINGTON, Dec. 1 /PRNewswire-USNewswi... Agency for International Development: ,, Chair...e Committee. ,, I am honored to be nominated by...United States Agency for International Development...e Agency. ,, Secretary of State Clinton has ex...

(Date:12/1/2009)... Barcelona, 30 November 2009. Performing surgica...e a chimera and has become a reality. This is demo...g NOTES (Natural Orifice Transluminal Endoscopy Su...s surgical access using the body,s natural orifice...t: lack of scars, shorter hospital stay and faster...

[0] CT Scan May Predict Colon Cancer Survival [0] UM Clinical Research Building awarded prestigious LEED Building Certification [0] New White Paper Details Six Common Bad Assumptions About Hearing Protection [0] Testimony Before the Senate Committee on Foreign Relations Administrator Designate Dr. Rajiv Shah December 1, 2009 [0] Hospital Clinic Barcelona and Massachusetts General Hospital extract rectal mass through anus

... Ethnic rhinoplasty will be discusse...American Society for Aesthetic Plastic Surgery (AS...nvention Center May 2-7, 2009. , ...both their individuality and ethnic identity. But...

... Non-surgical facial rejuvenation te...he Annual Meeting of the American Society for Aest...andalay Bay Hotel & Convention Center May 2-7,... can erase wrinkles, tighten the skin, and improve...

... Nashville hair transplant center, P...sed on expanding their serviceable region. PAI Nas...phis, Knoxville, Clarksville, Chattanooga, Birming...spread throughout Tennessee, Kentucky, and Alabama...

... As citizens search to protect thems...otections may actually be right under our nose. Br...ing this crisis , New Por...itizens are mobilizing to protect themselves by we...

...ed $750,000 by Avon Foundation for Breast Cancer A...nne Mandelblatt, MD, MPH, and Harriet Weiner have ...ion to walk to raise funds and awareness of breast... Lombardi. , , The team has been training since ...

...H1N1 strain lacks "virulent characteristics" of de...ay 2 (HealthDay News) -- The scope of the swine fl... thought, test results released Friday in Mexico s... people have died. , Mexico had reported about 2,5...

Ethnic Rhinoplasty: The "Classic" Nose Job is Not One Size Fits All Saving Face...No Need For A Knife! Hair Transplant Office Expands Serviceable Area Cleanose Personal Air Filters Offer Added Protection From Inhaled Viruses/ Swine Flu/ H1N1 and Other Inhaled Dangers Georgetown's Lombardi Comprehensive Cancer Center and the Capital Breast Care Center Pound the Pavement to Save Lives Scope of Swine Flu Outbreak in Mexico Might Be Smaller Than Thought

...ies is a national reference laboratory and a world...development. ARUP offers an extensive test menu of...al and anatomic pathology. Owned by the University...than half of the nation's university teaching hosp...

Medicine Products:

Antifungal Serum Level, Itraconazole Antidiuretic Hormone, Plasma Antidepressant Panel Anticochlear

Dendreon to Hold a Conference Call Tomorrow at 9:00 AM ET to Discuss Final Results of Phase 3 PROVENGE IM...( SEATTLE April 13 /- Dendreon Corporat...),Health